Seelos Therapeutics is a biotechnology business based in the US. Seelos Therapeutics shares (SEEL) are listed on the OTCQB and all prices are listed in US Dollars. Its last market close was $0.39 – a decrease of 27.79% over the previous week. Seelos Therapeutics employs 8 staff and has a trailing 12-month revenue of around $2 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.39 |
|---|---|
| 52-week range | $0.54 - $698.88 |
| 50-day moving average | $2.27 |
| 200-day moving average | $35.44 |
| Wall St. target price | $120.00 |
| PE ratio | 0.0019 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $361.07 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.39 from 2024-11-18
| 1 week (2024-11-15) | -27.79% |
|---|---|
| 1 month (2024-10-22) | -67.50% |
| 3 months (2024-08-22) | 18.15% |
| 6 months (2024-05-22) | -73.10% |
| 1 year (2023-11-22) | 129.55% |
|---|---|
| 2 years (2022-11-22) | -99.99% |
| 3 years (2021-11-22) | 6912 |
| 5 years (2019-11-22) | 3226.7524 |
Valuing Seelos Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Seelos Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Seelos Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 0x. In other words, Seelos Therapeutics shares trade at around 0x recent earnings.
| Revenue TTM | $2 million |
|---|---|
| Gross profit TTM | $-46,649,000 |
| Return on assets TTM | -261.11% |
| Return on equity TTM | -584.2% |
| Profit margin | 203.13% |
| Book value | $-135.50 |
| Market Capitalization | $397,985 |
TTM: trailing 12 months
We're not expecting Seelos Therapeutics to pay a dividend over the next 12 months.
Seelos Therapeutics's shares were split on a 1:16 basis on 26 September 2024 . So if you had owned 16 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Seelos Therapeutics shares – just the quantity. However, indirectly, the new 1500% higher share price could have impacted the market appetite for Seelos Therapeutics shares which in turn could have impacted Seelos Therapeutics's share price.
Over the last 12 months, Seelos Therapeutics's shares have ranged in value from as little as $0.5401 up to $698.8804. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (OTCQB average) beta is 1, while Seelos Therapeutics's is 1.939. This would suggest that Seelos Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Seelos Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-004, an gene therapy targeting gene and alpha synuclein; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; SLS-007, a peptidic inhibitor for NACore Parkinson disease; and SLS-009, a protein targeted autophagy for Alzheimer disease. Seelos Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York. .
Steps to owning and managing MRK, with 24-hour and historical pricing before you buy.
Steps to owning and managing LLY, with 24-hour and historical pricing before you buy.
Steps to owning and managing ISRG, with 24-hour and historical pricing before you buy.
Steps to owning and managing VRTX, with 24-hour and historical pricing before you buy.
Steps to owning and managing MCK, with 24-hour and historical pricing before you buy.
Steps to owning and managing UNH, with 24-hour and historical pricing before you buy.
Steps to owning and managing AMGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABT, with 24-hour and historical pricing before you buy.
Steps to owning and managing PFE, with 24-hour and historical pricing before you buy.
Steps to owning and managing JNJ, with 24-hour and historical pricing before you buy.